Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones

European Journal of Medicinal Chemistry

Volumn 86, Issue , 2014, Pages 797-805

  Shchekotikhin, Andrey E ^a,b   Glazunova, Valeria A ^c,d   Dezhenkova, Lyubov G ^a   Luzikov, Yuri N ^a   Buyanov, Vladimir N ^b   Treshalina, Helena M ^c   Lesnaya, Nina A ^c   Romanenko, Vladimir I ^c   Kaluzhny, Dmitry N ^e   Balzarini, Jan ^f   Agama, Keli ^g   Pommier, Yves ^g   Shtil, Alexander A ^c,d   Preobrazhenskaya, Maria N ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b MENDELEEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA   (Russian Federation)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d NATIONAL RESEARCH NUCLEAR UNIVERSITY MEPHI   (Russian Federation)

^e ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^f REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antitumor activity; Circumvention of multidrug resistance; DNA ligands; Naphtho 23 f indole 510 diones; Topoisomerase 1 2 inhibitors

Indexed keywords

3 AMINOMETHYL 4,11 DIHYDROXYNAPHTHOL[2,3 F]INDOLE 5,10 DIONE DERIVATIVE; 3 [(3 AMINOPYRROLIDIN 1 YL)METHYL] 4,11 DIHYDROXY 1H NAPHTHOL[2,3 F]INDOLE 5,10 DIONE; 3 [(4 AMINOPIPERIDIN 1 YL)METHYL] 4,11 DIHYDROXY 1H NAPHTHOL[2,3 F]INDOLE 5,10 DIONE; 3 [(4 AMINOPIPERIDIN 1 YL)METHYL] 4,11 DIHYDROXY 1H NAPHTHOL[2,3 F]INDOLE 5,10 DIONE DIHYDROCHLORIDE; 4,11 DIHYDROXY 3 [(PIPERIDIN 3 YLAMINO)METHYL] 1H NAPHTHOL[2,3 F]INDOLE 5,10 DIONE; 4,11 DIHYDROXY 3 [(PYRROLIDIN 3 YLAMINO)METHYL] 1H NAPHTHOL[2,3 F]INDOLE 5,10 DIONE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; INDOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; CALF THYMUS DNA; DNA; DNA TOPOISOMERASE INHIBITOR; NAPHTHOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG DNA BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA P 388; MOUSE; NONHUMAN; ANIMAL; BOVINE; C57BL MOUSE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DBA MOUSE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; K562 CELL LINE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL PROLIFERATION; CELL SURVIVAL; DNA; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDOLES; K562 CELLS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MOLECULAR STRUCTURE; NAPHTHOLS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 84907858575     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.09.021     Document Type: Article

References (49)

1. A. Rescifina, C. Zagni, M.G. Varrica, V. Pistará, A. Corsaro, Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling, Eur. J. Med. Chem. 74 (2014) 95-115.
2. Y. Liu, E. Peacey, J. Dickson, C.P. Donahue, S. Zheng, G. Varani, M.S. Wolfe, Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA, J. Med. Chem. 52 (2009) 6523-6526.
3. S. Dogra, P. Awasthi, S. Tripathi, T.P. Pradeep, M.S. Nair, R. Barthwal, NMRbased structure of anticancer drug mitoxantrone stacked with terminal base pair of DNA hexamer sequence d-(ATCGAT)2, J. Biomol. Struct. Dyn. (2013). http://dx.doi.org/10.1080/07391102.2013.809021.
4. Y. Pommier, DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition, Chem. Rev. 109 (2009) 2894-2902.
5. A. Romero, T. Caldés, E. Díaz-Rubio, M. Martín, Topoisomerase 2 alpha: a real predictor of anthracycline efficacy? Clin. Transl. Oncol. 14 (2012) 163-168.
6. C. Sheng, Z. Miao, W. Zhang, New strategies in the discovery of novel noncamptothecin topoisomerase I inhibitors, Curr. Med. Chem. 18 (2011) 4389-4409.
7. T.V.T. Le, S. Han, J. Chae, H.-J. Park, G-Quadruplex binding ligands: from naturally occurring to rationally designed molecules, Curr. Pharm. Des. 18 (2012) 1948-1972.
8. Y.R. Lee, D.S. Yu, Y.C. Liang, K.F. Huang, S.J. Chou, T.C. Chen, C.C. Lee, C.L. Chen, S.H. Chiou, H.S. Huang, New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinonederived small molecules, PLoS One 8 (2013) e56284.
9. X. Wan, W. Zhang, L. Li, Y. Xie, W. Li, N. Huang, A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinomewide selectivity modeling, J. Med. Chem. 56 (2013) 2619-2629.
10. Z. Liang, J. Ai, X. Ding, X. Peng, D. Zhang, R. Zhang, Y. Wang, F. Liu, M. Zheng, H. Jiang, H. Liu, M. Geng, C. Luo, Anthraquinone derivatives as potent inhibitors of c-Met kinase and the extracellular signaling pathway, ACS Med. Chem. Lett. 4 (2013) 408-413.
11. G. Cozza, A. Gianoncelli, M. Montopoli, L. Caparrotta, A. Venerando, F. Meggio, L.A. Pinna, G. Zagotto, S. Moro, Identification of novel protein kinase CK1 delta inhibitors through structure-based virtual screening, Bioorg. Med. Chem. Lett. 18 (2008) 5672-5675.
12. T.S. Feng, Z.Y. Yuan, R.Q. Yang, S. Zhao, F. Lei, X.Y. Xiao, D.M. Xing, W.H. Wang, Y. Ding, L.J. Du, Purgative components in rhubarbs: adrenergic receptor inhibitors linked with glucose carriers, Fitoterapia (2013) 236-246.
13. D. Shrimali, M.K. Shanmugam, A.P. Kumar, J. Zhang, B.K. Tan, K.S. Ahn, G. Sethi, Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer, Cancer Lett. 341 (2013) 139-149.
14. J.-H. Chiang, J.-S. Yang, C.-Y. Ma, M.-D. Yang, H.-Y. Huang, T.-C. Hsia, H.- M. Kuo, P.-P. Wu, T.-H. Lee, J.-G. Chung, Danthron, an anthraquinone derivative, induces DNA damage and caspase cascades-mediated apoptosis in SNU-1 human gastric cancer cells through mitochondrial permeability transition pores and Bax-triggered pathways, Chem. Res. Toxicol. 24 (2011) 20-29.
15. G.-Z. Zeng, J.-T. Fan, J.-J. Xu, Y. Li, N.-H. Tan, Apoptosis induction and G2/M arrest of 2-methyl-1, 3, 6-trihydroxy-9, 10-anthraquinone from Rubia yunnanensis in human cervical cancer Hela cells, Die Pharm. 68 (2013) 293-299.
16. H.-Y. Tu, A.-M. Huang, C.-H. Teng, T.-C. Hour, S.-C. Yang, Y.-S. Pu, C.-N. Lin, Anthraquinone derivatives induce G2/M cell cycle arrest and apoptosis in NTUB1 cells, Bioorg. Med. Chem. 19 (2011) 5670-5678.
17. D.-H. Shi, W. Huang, C. Li, Y.-W. Liu, S.-F. Wang, Design, synthesis and molecular modeling of aloe-emodin derivatives as potent xanthine oxidase inhibitors, Eur. J. Med. Chem. 75 (2014) 289-296.
18. D. Bhasin, J.P. Etter, S.N. Chettiar, M. Mok, P.-K. Li, Antiproliferative activities and SAR studies of substituted anthraquinones and 1, 4-naphthoquinones, Bioorg. Med. Chem. Lett. 23 (2013) 6864-6867.
19. A. Di Salvo, P. Dugois, D. Tandeo, M. Peltekian, P.K.T. Lin, Synthesis, cytotoxicity and DNA binding of oxoazabenzo[de]anthracenes derivatives in colon cancer Caco-2 cells, Eur. J. Med. Chem. 69 (2013) 754-761.
20. M. Rebucci, C. Michiels, Molecular aspects of cancer cell resistance to chemotherapy, Biochem. Pharmacol. 85 (2013) 1219-1226.
21. H.J. Broxterman, K.J. Gotink, H.M.W. Verheul, Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib, Drug. Resist. Updat. 12 (2009) 114-126.
22. M. Piekarski, A. Jelinska, Anthracyclines still prove effective in anticancer therapy, Mini Rev. Med. Chem. 13 (2013) 627-634.
23. M.-T. Ma, M. He, Y. Wang, X.-Y. Jiao, L. Zhao, X.-F. Bai, Z.-J. Yu, H.-Z. Wu, M.- L. Sun, Z.-G. Song, M.-J. Wei, MiR-487 a resensitizes mitoxantrone (MX)- resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2), Cancer Lett. 339 (2013) 107-115.
24. S. Sangthong, H. Ha, T. Teerawattananon, N. Ngamrojanavanich, N. Neamati, N. Muangsin, Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9, 10-dione derivatives, Bioorg. Med. Chem. Lett. 23 (2013) 6156-6160.
25. K. Pors, Z. Paniwnyk, P. Teesdale-Spittle, J.A. Plumb, E. Willmore, C.A. Austin, L.H. Patterson, Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian Cancer, Mol. Cancer Ther. 2 (2003) 607-610.
26. A.E. Shchekotikhin, A.A. Shtil, Y.N. Luzikov, T.V. Bobrysheva, V.N. Buyanov, M.N. Preobrazhenskaya, 3-Aminomethyl derivatives of 4, 11- dihydroxynaphtho[2, 3-f]indole-5, 10-dione for circumvention of anticancer drug resistance, Bioorg. Med. Chem. 13 (2005) 2285-2291.
27. L.G. Dezhenkova, O.Y. Susova, A.E. Shchekotikhin, M.N. Preobrazhenskaya, A.A. Shtil, Naphtho[2, 3-f]indole-5, 10-dione aminoalkyl derivatives: a new class of topoisomerase I inhibitors, Bull. Exp. Biol. Med. 145 (2008) 334-337.
28. X. Wang, Z. Chen, L. Tong, S. Tan, W. Zhou, T. Peng, K. Han, J. Ding, H. Xie, Y. Xu, Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs), Eur. J. Med. Chem. 65 (2013) 477-486.
29. J. Qiu, B. Zhao, Y. Shen, W. Chen, Y. Ma, Y. Shen, A novel p-terphenyl derivative inducing cell-cycle arrest and apoptosis in MDA-MB-435 cells through topoisomerase inhibition, Eur. J. Med. Chem. 68 (2013) 192-202.
30. S.-E. Park, I.-H. Chang, K.-Y. Jun, E. Lee, E.-S. Lee, Y. Na, Y. Kwon, 3-(3- Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIa catalytic inhibitor with low DNA damage, Eur. J. Med. Chem. 69 (2013) 139-145.
31. P.-C. Lv, K. Agama, C. Marchand, Y. Pommier, M. Cushman, Design, Synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA posphodiesterase I inhibitors, J. Med. Chem. 57 (2014) 4324-4336.
32. A.E. Shchekotikhin, L.G. Dezhenkova, O.Y. Susova, V.A. Glazunova, Y.N. Luzikov, Y.B. Sinkevich, V.N. Buyanov, A.A. Shtil, M.N. Preobrazhenskaya, Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties, Bioorg. Med. Chem. 15 (2007) 2651-2659.
33. A.E. Shchekotikhin, V.N. Buyanov, M.N. Preobrazhenskaya, Synthesis of 1- (omega-aminoalkyl)naphthoindolediones with antiproliferative properties, Bioorg. Med. Chem. 12 (2004) 3923-3930.
34. A.E. Shchekotikhin, E.P. Baberkina, K.F. Turchin, V.N. Buyanov, N.N. Suvorov, Naphtoindoles. 10. Synthesis of 4, 11-dihydroxynaphtho[2, 3-f]indole-5, 10- dione and some of its derivatives, Chem. Heterocycl. Compd. 37 (2001) 944-948.
35. V. Verebová, J. Adamcik, P. Danko, D. Podhradský, P. Mískovský, J. Stanícová, Anthraquinones quinizarin and danthron unwind negatively supercoiled DNA and lengthen linear DNA, Biochem. Biophys. Res. Commun. 444 (2014) 50-55.
36. R. Scott, Some comments on the BenesieHildebrand equation, Recl. Des. Trav. Chim. Des. Pays-Bas 75 (1956) 787-789.
37. T.S. Dexheimer, Y. Pommier, DNA cleavage assay for the identification of topoisomerase I inhibitors, Nat. Protoc. 3 (2008) 1736-1750.
38. S. Antony, M. Jayaraman, G. Laco, G. Kohlhagen, K.W. Kohn, M. Cushman, Y. Pommier, Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I, Cancer Res. 63 (2003) 7428-7435.
39. K. Wassermann, J. Markovits, C. Jaxel, G. Capranico, K.W. Kohn, Y. Pommier, Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II, Biochem. Pharmacol. 38 (1990) 38-45.
40. P. Pourquier, L.-M. Ueng, J. Fertala, D. Wang, H.-K. Park, J.M. Essigmann, M.- A. Bjornsti, Y. Pommier, Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages 7, 8- dihydro-8-oxoguanine and 5-hydroxycytosine, J. Biol. Chem. 274 (1999) 8516-8523.
41. Y. Pommier, J. Covey, D. Kerrigan, W. Mattes, J. Markovits, K.W. Kohn, Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines, Biochem. Pharmacol. 36 (1987) 3477-3486.
42. M.F. Brana, M. Cacho, A. Gradillas, B. de Pascual-Teresa, A. Ramos, Intercalators as anticancer drugs, Curr. Pharm. Des. 7 (2001) 1745-1780.
43. Y. Pommier, P. Pourquier, Y. Fan, D. Strumberg, Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme, Biochem. Biophys. Acta 1400 (1998) 83-105.
44. S.B. Howerton, A. Nagpal, L.D. Williams, Surprising roles of electrostatic interactions in DNA-ligand complexes, Biopolymers 69 (2003) 87-99.
45. A.E. Shchekotikhin, V.A. Glazunova, Y.N. Luzikov, V.N. Buyanov, O.Y. Susova, A.A. Shtil, M.N. Preobrazhenskaya, Synthesis and structureeactivity relationship studies of 4, 11-diaminonaphtho[2, 3-f]indolee5, 10-diones, Bioorg. Med. Chem. 14 (2006) 5241-5251.
46. B.B. Semenov, V.G. Granik, Chemistry of N-(1H-indol-3-ylmethyl)-N, N-dimethylamine (gramine): a review, Pharm. Chem. J. 38 (2004) 287-310.
47. F. Bunz, A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J.P. Brown, J.M. Sedivy, K.W. Kinzler, B. Vogelstein, Requirement for p53 and p21 to sustain G2 arrest after DNA damage, Science 282 (1998) 1497-1501.
48. A.E. Shchekotikhin, V.A. Glazunova, L.G. Dezhenkova, E.K. Shevtsova, V.F. Traven, J. Balzarini, H.S. Huang, A.A. Shtil, M.N. Preobrazhenskaya, The first series of 4, 11-bis[(2-aminoethyl)amino]anthra[2, 3-b]furane5, 10-diones: synthesis and antiproliferative characteristics, Eur. J. Med. Chem. 46 (2011) 423-428.
49. T. Balandin, E. Edelweis, N. Andronova, H. Treshalina, A. Sapozhnikov, S. Deev, Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenograft, Investig. New. Drugs 29 (2011) 22-32.